ZKS Köln Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2020
NCT04631666
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

ZKS Köln

Active Ingredients

Drugs in Phase 2 Trials (2)

dzif-10c (1 trial)

sars-cov-2 specific t cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Coronavirus Infections (Phase 2)

Severe Acute Respiratory Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2